APA aipamena

Wohl, D., Bhatti, L., Small, C., Edelstein, H., Zhao, H., Margolis, D., . . . Shaefer, M. (2015). The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Med.

Chicago Style aipamena

Wohl, DA, et al. "The ASSURE Study: HIV‐1 Suppression Is Maintained With Bone and Renal Biomarker Improvement 48 Weeks After Ritonavir Discontinuation and Randomized Switch to Abacavir/lamivudine + atazanavir." HIV Med 2015.

MLA aipamena

Wohl, DA, et al. "The ASSURE Study: HIV‐1 Suppression Is Maintained With Bone and Renal Biomarker Improvement 48 Weeks After Ritonavir Discontinuation and Randomized Switch to Abacavir/lamivudine + atazanavir." HIV Med 2015.